First approval for Kyowa Kirin's lead biologic, for ATL in Japan
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has received the first approval worldwide for its lead therapeutic biologic, in Japan for the chemokine [C-C motif] receptor 4-targeting antibody Poteligeo (mogamulizumab; KW-0761).